FGEN Logo

FibroGen, Inc. (FGEN) 

NASDAQ
Market Cap
$32.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
227 of 776
Rank in Industry
131 of 433

Largest Insider Buys in Sector

FGEN Stock Price History Chart

FGEN Stock Performance

About FibroGen, Inc.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human …

Insider Activity of FibroGen, Inc.

Over the last 12 months, insiders at FibroGen, Inc. have bought $121,354 and sold $0 worth of FibroGen, Inc. stock.

On average, over the past 5 years, insiders at FibroGen, Inc. have bought $381,993 and sold $5.25M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Wettig Thane (CEO) — $95,470. Adib Deyaa (Chief Medical Officer) — $25,884.

The last purchase of 22,123 shares for transaction amount of $25,884 was made by Adib Deyaa (Chief Medical Officer) on 2024‑06‑12.

List of Insider Buy and Sell Transactions, FibroGen, Inc.

2024-06-12PurchaseChief Medical Officer
22,123
0.023%
$1.17$25,884-65.47%
2024-03-07PurchaseCEO
50,000
0.0545%
$1.91$95,470-37.08%
2023-09-01Saledirector
2,000
0.002%
$1.03$2,060-6.74%
2023-08-04Saledirector
2,000
0.002%
$1.91$3,820-42.15%
2023-07-11Saledirector
2,000
0.0021%
$2.69$5,380-58.24%
2023-07-07SaleChief Executive Officer
1,880
0.0021%
$2.80$5,264-57.78%
2023-06-23SaleChief Commercial Officer
791
0.0009%
$16.53$13,075-92.77%
2023-06-14SaleSVP, China Operations
6,250
0.0068%
$16.79$104,925-92.86%
2023-06-13SaleSVP, China Operations
6,250
0.0066%
$17.60$110,000-93.28%
2023-06-09Saledirector
7,889
0.0084%
$17.19$135,622-92.99%
2023-06-09Saledirector
8,520
0.0091%
$17.20$146,571-92.99%
2023-06-09Saledirector
3,944
0.0042%
$17.17$67,717-92.99%
2023-06-09Saledirector
4,733
0.0051%
$17.19$81,367-92.99%
2023-06-08Saledirector
7,000
0.0073%
$17.45$122,185-93.28%
2023-06-08Saledirector
8,520
0.0088%
$17.44$148,591-93.28%
2023-06-07SaleChief Executive Officer
8,897
0.0093%
$17.04$151,583-92.99%
2023-06-07SaleSVP, China Operations
3,633
0.0038%
$17.04$61,894-92.99%
2023-06-07SaleEVP, Chief Medical Officer
2,042
0.0021%
$17.04$34,792-92.99%
2023-06-07SaleChief Commercial Officer
1,758
0.0018%
$17.04$29,951-92.99%
2023-06-07Saledirector
7,100
0.0079%
$18.03$127,987-92.99%

Insider Historical Profitability

14.14%
Wettig ThaneCEO
470178
0.4683%
$0.3227+7.99%
Adib DeyaaChief Medical Officer
82123
0.0818%
$0.3210
Conterno Enrique AChief Executive Officer
374722
0.3732%
$0.3227+14.48%
Lema Geralddirector
3500
0.0035%
$0.3210+19.61%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
PRIMECAP Management Co$33.89M14.514.42M-0.35%-$119,309.500.03
Armistice Capital Llc$18.65M7.987.94M-18.72%-$4.3M0.06
BlackRock$16.37M7.016.97M-3.29%-$557,847.69<0.0001
The Vanguard Group$15.13M6.476.44M-8.62%-$1.43M<0.0001
Acadian Asset Management$5.88M2.522.5M+1.42%+$82,086.840.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.